Janssen starts selling Yondelis in Korea
Published: 2008-11-19 06:46:00
Updated: 2008-11-19 06:46:00
Janssen Korea says it will start selling Yondelis (trabectedin), a treatment for soft-tissue sarcoma, from November 25. Yondelis will be the first new therapy to be commercialized in this indication in the last two decades.
Yondelis was originally isolated from the marine tunicate Ecteinascidi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
